Table 5:
Patients characteristics according to the administration of adjuvant therapy (R0 patients; n = 1662)
|
na |
Adjuvant therapy administration |
P* | ||
|---|---|---|---|---|
| No (n = 986) | Yes (n = 676) | |||
| Age, median (IQR) | 1659 | 57 (46;68) | 54 (44;64) | <0.001 |
| Males | 1661 | 464 (47%) | 368 (54%) | 0.003 |
| Myasthenia gravis | 1491 | 322 (36%) | 234 (39%) | 0.229 |
| T size, median (IQR) | 1270 | 6 (4;7) | 5 (4;6) | 0.015 |
| Masaoka stage | ||||
| 1 | 1644 | 571 (58%) | 75 (11%) | <0.001 |
| 2 | 296 (30%) | 316 (48%) | ||
| 3 | 78 (8%) | 217 (33%) | ||
| 4 | 35 (4%) | 56 (8%) | ||
| Diagnosis | ||||
| Thymoma WHO A-AB-B1 | 1662 | 664 (67%) | 256 (38%) | <0.001 |
| Thymoma WHO B2–B3 | 273 (28%) | 326 (48%) | ||
| Thymic carcinoma | 38 (4%) | 78 (12%) | ||
| NETT | 11 (1%) | 16 (2%) | ||
NETT: neuroendocrine thymic tumour.
aAnalysis performed on the R0 patients with appropriate information on the administration of adjuvant therapy and on the characteristics of interest.
*P-values based on Mann–Whitney U-test and χ2 test for continuous variables and categorical variables, respectively.